These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17637710)

  • 1. Thiazolidinediones and fluid retention.
    Kiryluk K; Isom R
    Kidney Int; 2007 Sep; 72(6):762-8. PubMed ID: 17637710
    [No Abstract]   [Full Text] [Related]  

  • 2. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
    Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract]   [Full Text] [Related]  

  • 3. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Heart failure while taking glitazones--what do we know today?].
    Halbritter R
    Dtsch Med Wochenschr; 2009 Jul; 134(28-29):1488; author reply 1488. PubMed ID: 19572255
    [No Abstract]   [Full Text] [Related]  

  • 5. Thiazolidinedione-induced edema in patients with heart failure.
    Stroup JS
    Am J Health Syst Pharm; 2007 Dec; 64(23):2426-30; author reply 2430. PubMed ID: 18029947
    [No Abstract]   [Full Text] [Related]  

  • 6. Thiazolidinedione associated volume overload and pulmonary hypertension.
    Michaelson J
    Ther Adv Cardiovasc Dis; 2008 Dec; 2(6):435-8. PubMed ID: 19124440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms.
    Wang F; Vergara C; Carabino J; Desilets A; Vasquez R
    Am J Health Syst Pharm; 2004 Aug; 61(15):1604-8. PubMed ID: 15372837
    [No Abstract]   [Full Text] [Related]  

  • 8. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do thiazolidinediones cause heart failure? A critical review.
    Tang WH
    Cleve Clin J Med; 2006 Apr; 73(4):390-7. PubMed ID: 16610400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
    Patel C; Wyne KL; McGuire DK
    Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment.
    Narang N; Armstead SI; Stream A; Abdullah SM; See R; Snell PG; McGavock J; Ayers CR; Gore MO; Khera A; de Lemos JA; McGuire DK
    Diab Vasc Dis Res; 2011 Apr; 8(2):101-8. PubMed ID: 21562061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones in heart failure: slippery when wet.
    Khush KK
    J Card Fail; 2008 Aug; 14(6):453-5. PubMed ID: 18672191
    [No Abstract]   [Full Text] [Related]  

  • 13. Thiazolidinedione-associated congestive heart failure and pulmonary edema.
    Jamieson A; Abousleiman Y
    Mayo Clin Proc; 2004 Apr; 79(4):571; author reply 575-7. PubMed ID: 15065625
    [No Abstract]   [Full Text] [Related]  

  • 14. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research profile. Is there a link? TZDs and congestive heart failure. Andrew Karter, PhD.
    Kordella T
    Diabetes Forecast; 2004 Jun; 57(6):98-100. PubMed ID: 15195634
    [No Abstract]   [Full Text] [Related]  

  • 16. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.
    Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R
    Diabetes Care; 2004 Jan; 27(1):256-63. PubMed ID: 14693998
    [No Abstract]   [Full Text] [Related]  

  • 17. The rise and fall of rosiglitazone.
    Nissen SE
    Eur Heart J; 2010 Apr; 31(7):773-6. PubMed ID: 20154334
    [No Abstract]   [Full Text] [Related]  

  • 18. Rosiglitazone or pioglitazone in type 2 diabetes?
    de Vries CS; Russell-Jones DL
    BMJ; 2009 Aug; 339():b3076. PubMed ID: 19690344
    [No Abstract]   [Full Text] [Related]  

  • 19. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rise and fall of rosiglitazone: reply.
    Slaoui M
    Eur Heart J; 2010 May; 31(10):1282-4. PubMed ID: 20499440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.